Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Operations (2022 - 2025)

Historic Cash from Operations for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to -$2.5 million.

  • bioAffinity Technologies' Cash from Operations fell 4511.17% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 1724.76%. This contributed to the annual value of -$7.3 million for FY2024, which is 2032.18% down from last year.
  • As of Q3 2025, bioAffinity Technologies' Cash from Operations stood at -$2.5 million, which was down 4511.17% from -$2.6 million recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Cash from Operations peaked at -$376141.0 during Q2 2022, and registered a low of -$2.6 million during Q2 2025.
  • In the last 4 years, bioAffinity Technologies' Cash from Operations had a median value of -$1.6 million in 2023 and averaged -$1.6 million.
  • As far as peak fluctuations go, bioAffinity Technologies' Cash from Operations crashed by 26155.3% in 2023, and later skyrocketed by 3001.74% in 2025.
  • bioAffinity Technologies' Cash from Operations (Quarter) stood at -$1.3 million in 2022, then dropped by 24.27% to -$1.6 million in 2023, then decreased by 3.77% to -$1.7 million in 2024, then tumbled by 47.89% to -$2.5 million in 2025.
  • Its Cash from Operations was -$2.5 million in Q3 2025, compared to -$2.6 million in Q2 2025 and -$1.6 million in Q1 2025.